This article compiles all of the data from Generics Bulletin’s 2023 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
This week has seen Generics Bulletin publish its annual Top 50 ranking for 2023 of the leading companies across the generics and biosimilars industry.
Across three separate articles, we showed how the global top ten companies are evolving, including two new entrants; looked at...
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.
Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.
